缓释辅料市场－2026-2031年预测

缓释辅料市场预计将从 2025 年的 16.39 亿美元成长到 2031 年的 25.36 亿美元，维持 7.55% 的复合年增长率。

缓释辅料市场是整个医药辅料产业中一个特殊且重要的细分市场，专注于控制和维持药物从製剂中释放的功能性成分。这些辅料旨在改变活性药物成分（API）的溶解、扩散或侵蚀，从而延长疗效、减少给药频率并提高患者依从性。这些功能性材料主要用于片剂和胶囊等口服固态製剂，在开发满足不断变化的临床和以患者为中心的先进药物递送系统中发挥着至关重要的作用。

市场成长的关键驱动因素之一是患者对更容易服用的剂型的需求不断增长，尤其是在老年人和儿童等特定人群中。对于这些族群而言，简化给药方案（例如每日一次或减少给药频率）对于提高用药依从性和治疗效果至关重要。缓释製剂正是为了满足这一需求，这极大地激励了药物研发人员将特殊的控制释放辅料应用于新型和生命週期管理的产品。这种人口趋势也支撑了对创新辅料解决方案的持续需求。

市场成长也受到药用聚合物应用范围不断扩大和持续进步的推动，而药用聚合物正是缓释机制的核心技术。羟丙甲纤维素（HPMC）、乙基纤维素、聚乙酸乙烯酯和各种聚甲基丙烯酸酯等聚合物经过精心设计，能够精确控制药物释放动力学。从简单的粘合剂发展到能够实现标靶释放曲线（例如，pH依赖性、时间控制）的先进多功能辅料，是推动创新的主要动力。这些聚合物的性能、稳定性以及监管合规性对于製剂研发人员开发复杂的学名药和新型缓释製剂至关重要。

口服给药作为首选给药途径的主导地位对市场产生了重大影响。口服剂型在病患接受度、生产扩充性和成本效益方面具有无可比拟的优势。在此领域，缓释片和胶囊的研发是提高药物性能的重要方向。与新型给药途径相比，监管机构对口服缓释技术的相对认可加快了其研发和核准进程，鼓励製药公司利用缓释辅料来提升产品价值和差异化优势。

宏观层面的一个重要驱动因素是全球抗菌药物抗药性（AMR）的挑战。不合理使用速效抗生素，尤其是由于复杂的给药方案导致患者依从性差，被认为是抗药性出现的重要因素。缓释製剂能够以更少的剂量维持更长时间的有效药物浓度，有助于完成整个疗程并提高患者依从性，进而降低抗药性的风险。这项公共卫生迫切需求促使人们探索抗感染药物的缓释策略，并为相关辅料技术开闢了一条独特的成长路径。

市场也受益于製药公司利用药物递送技术（包括药物输送）来实现产品差异化并延长其商业生命週期的更广泛趋势，尤其是在专利到期的情况下。将现有活性药物成分 (API) 重新配製成缓释剂型，透过提供临床益处、提高市场竞争力以及提供生命週期管理途径，推动了对支持此类创新的辅料的需求。

从区域来看，北美仍然是一个关键且成熟的市场。其主导地位得益于众多拥有强大研发能力的跨国製药公司、积极开发复杂学名药（包括缓释产品）的蓬勃发展的学名药产业，以及美国食品药物管理局(FDA) 清晰的法规结构。该地区对先进药物递送技术和以患者为中心的剂型的关注，持续推动对高性能辅料的高需求。

同时，亚太地区被定位为高成长且潜力巨大的市场。这主要得益于该地区药品生产能力的快速扩张、医疗基础设施投资的不断增加、需要长期用药的慢性病患者人数的上升，以及全球供应商为满足不断增长的市场需求而日益本地化的辅料生产。随着医药标准和创新技术的不断发展，该地区蕴藏着巨大的成长机会。

在竞争激烈的市场环境中，主要的特种化学品和辅料生产商凭藉产品系列的广度、技术专长、产品稳定性、法规支援以及向配方师提供可靠科学数据的能力展开竞争。为了拓展商业性影响力，企业透过併购和合作等策略活动屡见不鲜。

总之，缓释辅料市场是现代以病人为中心的药物研发不可或缺的一部分。其成长动力源自于提高用药依从性的持续需求、聚合物科学的进步、药物传递策略在提升治疗价值的应用。未来发展将受到以下因素的影响：能够响应生理触发的多功能智慧辅料的创新、对复杂学名药日益增长的需求，以及对用于支持难溶性药物等原料药性药物缓释製剂的辅料的需求。在该市场取得成功需要对製剂科学有深刻的理解，与药物研发人员密切合作，并致力于功能性材料设计的品质和创新。

本报告的主要优势：

• 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
• 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
• 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
• 可操作的建议：利用这些见解，在快速变化的环境中製定策略决策，发展新的商业机会和收入来源。
• 受众广泛：对Start-Ups、研究机构、顾问公司、中小企业和大型企业都很有用且经济实惠。

您打算如何使用这份报告？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

• 2021年至2025年的历史数据和2026年至2031年的预测数据
• 成长机会、挑战、供应链前景、法规结构与趋势分析
• 竞争定位、策略和市场占有率分析
• 按业务板块和地区（包括国家）分類的收入和预测评估
• 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策与法规
• 策略建议

第四章 技术展望

第五章 缓释辅料市场（依类型划分）

• 介绍
• 聚合物
• 脂质
• 微球

6. 依产品类型分類的缓释辅料市场

• 介绍
• 片剂和胶囊
• 修补
• 植入
• 其他的

7. 依给药途径分類的缓释辅料市场

• 介绍
• 口服
• 注射
• 经皮吸收剂
• 其他的

8. 按地区分類的控释辅料市场

• 介绍
• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 合併、收购、协议和合作
• 竞争对手仪錶板

第十章：公司简介

• BASF SE
• International Flavors & Fragrances, Inc.
• Ashland
• Evonik Industries
• Croda International Plc
• Gattefosse
• Merck KGaA
• MEGGLE GmbH & Co. KG
• Roquette Freres
• CD Formulation

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 调查方法
• 简称

Sustained Release Excipients Market, sustaining a 7.55% CAGR, is anticipated to reach USD 2.536 billion in 2031 from USD 1.639 billion in 2025.

The sustained release excipients market is a specialized and critical segment within the broader pharmaceutical excipients industry, focused on the functional ingredients that enable controlled and prolonged drug release from a dosage form. These excipients are engineered to modulate the dissolution, diffusion, or erosion of the active pharmaceutical ingredient (API), thereby extending its therapeutic effect, reducing dosing frequency, and improving patient compliance. Primarily utilized in oral solid dosage forms like tablets and capsules, these functional materials are fundamental to developing advanced drug delivery systems that meet evolving clinical and patient-centric needs.

A primary driver of market growth is the increasing demand for patient-friendly dosage forms tailored to specific populations, particularly the elderly and pediatric patients. For these groups, simplified dosing regimens-achieved through once-daily or less-frequent administration-are crucial for improving adherence and therapeutic outcomes. Sustained release formulations address this need directly, creating a strong incentive for pharmaceutical developers to incorporate specialized release-modifying excipients into new and lifecycle-managed products. This demographic trend underpins a sustained demand for innovative excipient solutions.

The market is further propelled by the expanding use and continuous advancement of pharmaceutical polymers, which constitute the core technology for most sustained release mechanisms. Polymers such as hypromellose (HPMC), ethyl cellulose, polyvinyl acetate, and various polymethacrylates are engineered to provide precise control over drug release kinetics. Their evolution from simple binding agents to sophisticated, multifunctional excipients capable of enabling targeted release profiles (e.g., pH-dependent, time-controlled) is a key innovation driver. The performance, consistency, and regulatory acceptance of these polymers make them indispensable for formulators developing complex generic and novel sustained release products.

The dominance of oral drug delivery as the preferred administration route significantly influences the market. Oral dosage forms offer unparalleled advantages in terms of patient acceptance, manufacturing scalability, and cost-effectiveness. Within this segment, the development of sustained release tablets and capsules represents a major focus area for improving drug performance. The relative regulatory familiarity with oral modified-release technologies, compared to more novel delivery routes, facilitates development and approval, encouraging pharmaceutical companies to leverage sustained release excipients to enhance product value and differentiation.

A notable macro-level driver is the global challenge of antimicrobial resistance (AMR). Inappropriate use of immediate-release antibiotics, often due to complex dosing schedules leading to patient non-adherence, is a recognized contributor to resistance. Sustained release formulations that maintain effective drug concentrations over longer periods with fewer doses can support more complete treatment courses and improved adherence, potentially mitigating one factor in resistance development. This public health imperative encourages exploration of controlled-release strategies for anti-infectives, creating a specific, though niche, growth avenue for relevant excipient technologies.

The market also benefits from the broader trend of pharmaceutical companies utilizing drug delivery technologies, including sustained release, to differentiate products and extend commercial lifecycles, especially in the face of patent expirations. Reformulating an existing API into a controlled-release version can offer clinical benefits, improve market competitiveness, and provide a pathway for lifecycle management, thereby driving demand for the excipients that enable such innovations.

Geographically, North America remains a mature and dominant market. This leadership is supported by a concentration of multinational pharmaceutical companies with extensive R&D capabilities, a robust generic drug industry active in developing complex generics (including modified-release products), and a well-defined regulatory framework from the U.S. Food and Drug Administration (FDA). The region's focus on advanced drug delivery and patient-centric dosage forms sustains high demand for high-performance excipients.

Concurrently, the Asia-Pacific region is identified as a high-growth market with significant potential. This is driven by the rapid expansion of regional pharmaceutical manufacturing capabilities, increasing investment in healthcare infrastructure, a growing burden of chronic diseases requiring long-term medication, and the rising localization of excipient production by global suppliers to serve this expanding market. The region presents a substantial opportunity for growth as pharmaceutical standards and innovation continue to advance.

The competitive landscape features major specialty chemical and excipient manufacturers that compete on the basis of product portfolio breadth, technical expertise, consistency, regulatory support, and the ability to provide robust scientific data to formulators. Strategic activities, including mergers, acquisitions, and partnerships, are common as companies seek to expand their technology platforms, gain access to novel polymer chemistries, and strengthen their global commercial footprint.

In conclusion, the sustained release excipients market is integral to the development of modern, patient-centered pharmaceuticals. Its growth is underpinned by enduring needs for improved medication adherence, the sophistication of polymer science, and the strategic use of drug delivery to enhance therapeutic value. Future development will be shaped by innovations in multifunctional and "smart" excipients that respond to physiological triggers, the increasing demand for complex generic products, and the need for excipients that support the development of sustained release formulations for challenging APIs, including poorly soluble drugs. Success in this market requires a deep understanding of formulation science, close collaboration with pharmaceutical developers, and a commitment to quality and innovation in functional material design.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Sustained Released Excipients Market Segmentation

• By Type
• Polymers
• Lipids
• Micrspheres
• By Product Type
• Tablets & Capsules
• Patches
• Implants
• Others
• By Route of Administration
• Oral
• Injectables
• Transdermal
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SUSTAINED RELEASED EXCIPIENTS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Polymers
• 5.3. Lipids
• 5.4. Micrspheres

6. SUSTAINED RELEASED EXCIPIENTS MARKET BY PRODUCT TYPE

• 6.1. Introduction
• 6.2. Tablets & Capsules
• 6.3. Patches
• 6.4. Implants
• 6.5. Others

7. SUSTAINED RELEASED EXCIPIENTS MARKET BY ROUTE OF ADMINISTRATION

• 7.1. Introduction
• 7.2. Oral
• 7.3. Injectables
• 7.4. Transdermal
• 7.5. Others

8. SUSTAINED RELEASED EXCIPIENTS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. BASF SE
• 10.2. International Flavors & Fragrances, Inc.
• 10.3. Ashland
• 10.4. Evonik Industries
• 10.5. Croda International Plc
• 10.6. Gattefosse
• 10.7. Merck KGaA
• 10.8. MEGGLE GmbH & Co. KG
• 10.9. Roquette Freres
• 10.10. CD Formulation

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations